Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC)

P. Preti, G. Poggi, A. M. Cuomo, F. S. Robustelli Della Cuna, A. Zambelli, L. Pavesi

Research output: Contribution to journalArticlepeer-review

Abstract

We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.

Original languageEnglish
Pages (from-to)492-495
Number of pages4
JournalJournal of Chemotherapy
Volume10
Issue number6
Publication statusPublished - 1998

Keywords

  • Carboplatin
  • Etoposide
  • Ifosfamide
  • Lung cancer
  • Non small-cell lung cancer

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II Study with Ifosfamide, Carboplatin, Etoposide (ICE Regimen) at Intermediate Dosage for Advanced Non Small Cell Lung Cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this